Effect of methylene blue on treatment of COVID-19 patients

Phase 3

Completed

• Conditions: Covid-19.; COVID-19, Treatment; U07.1

• Registration Number: IRCT20191228045924N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2020-10-06

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Confirmed case of Covid-19 (by RT-PCR, HRCT)
Admission to intensive care unit
Need for intubation and mechanical ventilation (PaO2/FiO2 < 100-200)
Written informed consent

Exclusion Criteria

Pregnancy and breastfeeding
G6PDH deficiency
Severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2)
Active chronic hepatitis
Severe hepatic disease defined by GOT or GPT levels three times above the normal upper limit
Patients with history of allergic reaction or significant sensitivity to methylene blue
Treatment with immunosuppressive agents
Use of other investigational drugs in the moment of inclusion

Study & Design

• Study Type: interventional
• Study Design: Not specified